These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37987175)

  • 21. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
    Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
    Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
    Saljoughian N; Taheri T; Zahedifard F; Taslimi Y; Doustdari F; Bolhassani A; Doroud D; Azizi H; Heidari K; Vasei M; Namvar Asl N; Papadopoulou B; Rafati S
    PLoS Negl Trop Dis; 2013; 7(4):e2174. PubMed ID: 23638195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
    Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
    Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of negative air ions (NAIs) on Leishmania major: A novel tool for treatment of zoonotic cutaneous leishmaniasis (ZCL).
    Badirzadeh A; Najm M; Hemphill A; Alipour M; Hasanpour H; Masoori L; Karimi P
    PLoS One; 2022; 17(9):e0274124. PubMed ID: 36074764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice.
    Mahmoudzadeh-Niknam H; Kiaei SS; Iravani D
    Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling.
    Hugentobler F; Yam KK; Gillard J; Mahbuba R; Olivier M; Cousineau B
    PLoS One; 2012; 7(2):e30945. PubMed ID: 22348031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with Live Attenuated L. Major and TLR4 Agonist Promotes a Th1 Immune Response and Induces Protection against L. Major Infection in BALB/c Mice.
    Noorpisheh Ghadimi S; Farjadian S; Hatam GR; Kalani M; Sarkari B
    Iran J Immunol; 2018 Jun; 15(2):74-83. PubMed ID: 29947337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term protection conferred by Leishvacin® against experimental Leishmania amazonensis infection in C57BL/6 mice.
    Carneiro MB; de Andrade e Sousa LM; Vaz LG; Dos Santos LM; Vilela L; de Souza CC; Gonçalves R; Tafuri WL; Afonso LC; Côrtes DF; Vieira LQ
    Parasitol Int; 2014 Dec; 63(6):826-34. PubMed ID: 25102355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process.
    Okwor I; Liu D; Beverley SM; Uzonna JE
    Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13951-6. PubMed ID: 19666482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caffeic acid combined with autoclaved Leishmania major boosted the protection of infected BALB/c mice by enhancing IgG2 production, IFN-γ/TGF-β and iNO synthase/arginase1 ratios, and the death of infected phagocytes.
    Belkhelfa-Slimani R; Djerdjouri B
    Inflammopharmacology; 2018 Apr; 26(2):621-634. PubMed ID: 28988279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
    Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
    Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
    Pirdel L; Farajnia S
    Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leishmania tropica: suggestive evidences for the effect of infectious dose on pathogenicity and immunogenicity in an experimental model.
    Rostamian M; Jafari D; Abolghazi M; Farahani H; Niknam HM
    Parasitol Res; 2018 Sep; 117(9):2949-2956. PubMed ID: 29978420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
    Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
    Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic properties of empty pcDNA3 plasmid against zoonotic cutaneous leishmaniasis in mice.
    Montakhab-Yeganeh H; Shafiei R; Najm M; Masoori L; Aspatwar A; Badirzadeh A
    PLoS One; 2022; 17(2):e0263993. PubMed ID: 35167596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity.
    Saini S; Ghosh AK; Das S; Singh R; Abhishek K; Verma S; Kumar A; Mandal A; Purkait B; Sinha KK; Das P
    Vaccine; 2018 Feb; 36(9):1190-1202. PubMed ID: 29395522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana.
    Dey R; Natarajan G; Bhattacharya P; Cummings H; Dagur PK; Terrazas C; Selvapandiyan A; McCoy JP; Duncan R; Satoskar AR; Nakhasi HL
    J Immunol; 2014 Oct; 193(7):3513-27. PubMed ID: 25156362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-4 Responsive Dendritic Cells Are Dispensable to Host Resistance Against
    Osero BO; Cele Z; Aruleba RT; Maine RA; Ozturk M; Lutz MB; Brombacher F; Hurdayal R
    Front Immunol; 2021; 12():759021. PubMed ID: 35154068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.